Pneumocystis Clinical Trial
Official title:
Performance of Non-targeted and/or Non-invasive Respiratory Samples for the Rapid Diagnosis of Pneumocystis Pneumonia Using the BDMAX TM Molecular Biology Platform (Becton Dickinson)
Incidence and morbi-mortality of Pneumocystis pneumonia (PCP) are increasing. Early and fast diagnosis and treatment improve PCP prognosis. Biological diagnosis is based on the detection of Pneumocystis jirovecii, mainly by PCR, in broncho-alveolar lavage (BAL) obtained from bronchial fibroscopy. However this invasive exam is not always possible in emergency in suspected patient and others non invasive (sputa) and/or non-targeted (bronchial aspiration) are sent to the laboratory (25% of cases, data from the Grenoble University Hospital). Diagnosis performances of these non invasive/non-targeted samples are not clearly established. In this study, the investigators aimed to establish the diagnosis value of non-invasive and/or non-targeted respiratory samples (oral fluids, sputa and bronchial aspiration) for the PCP diagnosis, compared to the gold-standard (Pneumocystis PCR on BAL, beta-D-glucans testing on serum and radio-clinical records).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 | |
Enrolling by invitation |
NCT03856229 -
Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS
|
N/A | |
Not yet recruiting |
NCT04851015 -
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
|
Phase 3 | |
Completed |
NCT05707156 -
Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
|
||
Completed |
NCT00870857 -
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
|
N/A | |
Recruiting |
NCT02944045 -
Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
|
Phase 3 |